Welcome to our dedicated page for Guardian Pharmacy Services SEC filings (Ticker: GRDN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Guardian Pharmacy Services, Inc. filings document the reporting obligations of a NYSE-listed long-term care pharmacy services company with Class A common stock. Recent Form 8-K filings furnish operating results, financial guidance, investor presentation materials, and exhibits tied to the company’s pharmacy services business.
Proxy and current-report filings also cover board elections, advisory compensation votes, stockholder voting results, material stock purchase agreements, lock-up arrangements, and conversion-related disclosures involving Class A and Class B common stock. These records describe governance, ownership, capital-structure mechanics, registered securities, and matters linked to the company’s September 2024 corporate reorganization.
Guardian Pharmacy Services reported strong 2025 results and raised its 2026 profit outlook. Revenue for 2025 grew to $1.45 billion, with net income attributable to the company improving to $48.96 million from a prior-year loss, and Adjusted EBITDA rising to $115.15 million.
For 2026, Guardian kept its revenue outlook at $1.40–$1.42 billion but increased Adjusted EBITDA guidance to $120–$124 million, reflecting an estimated run-rate of about $110 million exiting 2025. The company ended the year with $65.6 million in cash and no long-term debt outstanding on its $75 million credit facility.
Guardian highlighted operational gains, including the acquisition of North Ridge Pharmacy in Montana, vaccine volume growth with more than 120,000 residents vaccinated in 2025, and an annualized return on equity of about 27%. Management emphasized confidence in the long-term care pharmacy model despite new IRA drug pricing changes.
Forbes Kendall reported acquisition or exercise transactions in this Form 4 filing.
Guardian Pharmacy Services insider Kendall Forbes received an equity award. Forbes was granted 8,952 restricted stock units of Class A common stock at no cash cost, which will vest in full on March 1, 2029. After this grant, Forbes directly holds 799,928 shares or units of Class A common stock.
Morris David K reported acquisition or exercise transactions in this Form 4 filing.
Guardian Pharmacy Services, Inc. director and officer Morris David K reported an equity award of 8,952 shares of Class A common stock on March 1, 2026. The award is in the form of restricted stock units granted at $0.00 per share, bringing his directly held Class A shares to 442,327.
The footnote explains these are restricted stock units that settle one-for-one into Class A common stock when they vest in full on March 1, 2029, highlighting that the award’s value depends on future vesting.
Burke Fred reported acquisition or exercise transactions in a Form 4 filing for GRDN. The filing lists transactions totaling 75,000 shares. Following the reported transactions, holdings were 75,000 shares.
Guardian Pharmacy Services executive Forbes Kendall received a grant of 50,000 stock options on February 11, 2026. The options have an exercise price of $34.59 per share and relate to Class A common stock. They vest and become fully exercisable on February 11, 2029, and expire on February 11, 2036. Following this grant, Kendall beneficially owns 50,000 derivative securities directly.
Morris David K reported acquisition or exercise transactions in a Form 4 filing for GRDN. The filing lists transactions totaling 50,000 shares. Following the reported transactions, holdings were 50,000 shares.
Brown Advisory Inc and affiliated entities filed an amended Schedule 13G reporting their passive ownership in Guardian Pharmacy Services, Inc. They disclose beneficial ownership of 1,644,569 shares of Class A common stock, representing 4.54% of the class as of 12/31/2025.
The shares are held across Brown Advisory Inc, Brown Investment Advisory & Trust Co, Brown Advisory LLC, Signature Financial Management, Inc., and Brown Advisory Ltd, through investment companies and other managed accounts. The group certifies the holdings are in the ordinary course of business and not for the purpose of changing or influencing control of Guardian Pharmacy Services.
Guardian Pharmacy Services, Inc. (GRDN) received an amended Schedule 13G from a Wellington-affiliated group reporting a minority ownership position. Wellington Management Group LLP, Wellington Group Holdings LLP, and Wellington Investment Advisors Holdings LLP report beneficial ownership of 1,123,132 shares of common stock, representing 3.1% of the class as of the event date 12/31/2025.
The group reports no sole voting or dispositive power, with shared voting power over 793,969 shares and shared dispositive power over 1,123,132 shares. The securities are owned of record by clients of Wellington investment advisers, and no individual client is said to hold more than five percent of the class. The filing certifies the holdings are in the ordinary course of business and not for the purpose of changing or influencing control of Guardian Pharmacy Services.
BlackRock, Inc. reports a passive ownership stake in Guardian Pharmacy Services, Inc. Class A stock. As of the event date, BlackRock beneficially owned 1,507,822 Class A shares, representing 4.2% of the class. It held sole voting power over 1,473,050 shares and sole dispositive power over 1,507,822 shares, with no shared voting or dispositive power.
The filing is an amended Schedule 13G/A, indicating that the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Guardian Pharmacy Services. Various underlying clients have rights to dividends or sale proceeds, but no single client has more than five percent of the total outstanding common shares.
Guardian Pharmacy Services, Inc. reiterated its previously issued financial guidance for the full year ended December 31, 2025 and shared an early financial outlook for 2026. These updates were released through a press release that is furnished as an exhibit.
The company also prepared an investor presentation about its business for use at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 at approximately 4:30 p.m. Pacific Time, as well as in meetings with investors, analysts, and other interested parties. Both the press release and the presentation are provided as supplemental materials to inform the market about current expectations and business positioning.